Many clinical trials, including trials evaluating drugs targeting ATR, ATM, WEE1, checkpoint kinase 1/2 (CHK1/2), BRCA1/2 and RAD51, have been designed to evaluate interference with DDR pathways to overcome platinum and PARPi resistance in ovarian cancer. This evidence concerns the gene CHEK1 and ovarian carcinoma.